conflict of interest

(WATCH) FDA does an about-face; requests investigation of Alzheimer drug approval

After originally defending her agency’s process, FDA acting commissioner Janet Woodcock has now requested a review of the FDA’s controversial approval of an Alzheimer’s drug. There has been widespread criticism of last month’s approval of aducanumab sold under the brand

(WATCH) FDA does an about-face; requests investigation of Alzheimer drug approval Read More »

Scroll to Top